Clinical Trials for PF-02341066

2 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCPHI1255
09/28/2013
Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
TreatmentCOGADVL0912
04/05/2011
PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.